Zygolide brings the first FDA-approved generic pergolide for PPID
CURRENT FULL VERSION: A new generic option has arrived for one of equine practice’s most familiar chronic endocrine diseases. In January 2026, the FDA announced approval of Zygolide, Dechra’s pergolide tablet for control of clinical signs associated with pituitary pars intermedia dysfunction, or PPID, in horses. The agency said Zygolide is the first FDA-approved generic to Prascend and found it bioequivalent to the brand product. (fda.gov)
That matters because pergolide has been central to PPID management for years. Prascend was first approved in 2011, giving veterinarians an on-label product for a disease that had long been treated with pergolide in other forms. Current consensus recommendations from the Equine Endocrinology Group continue to place pergolide at the center of medical management, with an initial recommended dose of 2 mcg/kg once daily and U.S. label guidance not to exceed 4 mcg/kg daily. (fda.gov)
FDA records show Zygolide was approved under ANADA 200-823 on December 19, 2025, with Dechra as sponsor. In the approval summary, the agency states that the 1 mg tablet was shown to be bioequivalent to 1 mg Prascend in an in vivo blood-level study in horses, with no serious adverse events reported during that study. The product labeling also points to historical effectiveness data for pergolide tablets: in an open-label field study, 86 of 113 evaluable horses, or 76.1%, were considered treatment successes at Day 180, while 41.6% required a dose increase at Day 90. (animaldrugsatfda.fda.gov)
The commercial positioning appears to focus on day-to-day usability. Promotional materials published by The Horse describe Zygolide as peppermint-flavored and designed to support consistent daily administration. Other source material tied to the campaign highlights a half-scored tablet intended for dosing flexibility. The same advertising series also uses owner-facing language such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best so you can enjoy more happy moments together,” suggesting Dechra is marketing the product not only as a generic substitute but as a quality-of-life tool for long-term management. Another ad in the series calls it a “cost-effective treatment,” with a pricing footnote tied to Valley Vet as of March 4, 2026. Those features may resonate in PPID cases where long-term adherence is the real challenge, especially when horses become reluctant to take medication or when dosing needs to be fine-tuned over time. (thehorse.com)
Even so, the label underscores that pergolide is not a frictionless medication. Zygolide should not be crushed because splitting or crushing pergolide tablets may increase human exposure, and pregnant or lactating women are advised to wear gloves when administering it. The label also says treatment may cause inappetence, which was reported in roughly one-third of horses during the pre-approval field study, mostly early in treatment. For veterinarians, those details are a reminder that product selection is only one part of successful PPID management; client education, follow-up testing, and early troubleshooting still do much of the heavy lifting. (fda.gov)
Industry reaction so far has been more practical than dramatic. Dechra’s own materials frame Zygolide as a new option in equine endocrinology, while trade coverage has emphasized availability through equine pharmacy channels and the possibility of a more cost-conscious alternative. The company’s advertising language adds another clue about how it plans to compete: not just on generic equivalence, but on affordability, owner experience, and preserving the horse-owner bond over years of treatment. I didn’t find substantial independent expert commentary yet from academic internists or major veterinary associations specifically reacting to Zygolide’s launch, which likely reflects how recent the approval is. What is clear from existing PPID guidance and long-term treatment reporting is that adherence, monitoring, and individualized dose adjustment remain more important than branding alone. (equinefacilitydesign.com)
Why it matters: For veterinary professionals, Zygolide could modestly reshape the economics and logistics of PPID care without changing the clinical standard itself. A generic pergolide may help some pet parents stay on therapy longer, particularly in older horses with concurrent laminitis risk, muscle loss, coat changes, or polyuria/polydipsia that require sustained management. If pricing is competitive and supply is reliable, practices may gain another tool for reducing treatment drop-off in chronic cases. Dechra’s own campaign explicitly leans on “cost-effective treatment” messaging and on helping horses “feel their best,” which fits the practical reality that success in PPID care is measured over months and years, not at the point of prescription alone. But veterinarians will still need to guide pet parents on dosing, seasonal and follow-up ACTH testing, appetite-related adverse effects, and safe tablet handling. (fda.gov)
What to watch: The next signals will be distributor uptake, real-world price comparisons against Prascend, and whether equine clinicians see measurable improvements in adherence tied to flavoring, tablet design, or availability over the rest of 2026. It will also be worth watching whether Dechra’s marketing claims around cost-effectiveness and owner-centered quality of life translate into meaningful differences in how practices discuss long-term PPID treatment with clients. (equinefacilitydesign.com)